UK MND patient charity providing trial recruitment, patient access, and advocacy expertise in European ALS clinical research consortia.
The Motor Neurone Disease Association (MNDA) is the UK's principal charity dedicated to motor neurone disease (MND/ALS), combining patient support, research funding, and disease advocacy. In H2020 clinical research, they contribute as a specialist patient organisation partner in Phase II randomised controlled trials, providing access to the UK MND patient community, supporting trial recruitment, and ensuring research design reflects patient priorities and lived experience. Their value to a clinical consortium is distinct from academic or biotech partners: they bring ethical legitimacy, recruitment reach, and patient-centred outcome expertise that cannot be replicated by a laboratory. Both of their H2020 participations were in large, multi-site European RCTs testing experimental ALS treatments, confirming their established position within the European ALS clinical research network.
Participated in both MIROCALS (IL-2 immunotherapy RCT) and TUDCA-ALS (neuroprotection RCT), the two primary roles consistent with patient organisation support in Phase II trials.
MIROCALS focused on low-dose IL-2 and regulatory T cells as anti-inflammatory therapy, an area where the MNDA provided patient-side expertise and community access.
TUDCA-ALS tested tauroursodeoxycholic acid as a neuroprotective add-on treatment, with MNDA's involvement grounding the trial in clinical and patient relevance.
Consistent non-lead participant role across both projects reflects the formal advocacy and patient representation function recognised by EU-funded clinical consortia.
Early H2020 involvement (MIROCALS, 2015) centred on immunotherapy — specifically the use of low-dose interleukin-2 to enhance regulatory T cells and suppress neuroinflammation, a mechanistic hypothesis grounded in immune biology. By the later project (TUDCA-ALS, 2018), the focus shifted toward direct neuroprotection using bile acid derivatives (deoxycholic acids/TUDCA), representing a different therapeutic axis altogether — less about immune modulation, more about direct neuronal survival. This suggests the MNDA actively pursued involvement across multiple mechanistic approaches to ALS, rather than anchoring to a single scientific hypothesis.
The MNDA is broadening its clinical trial partnerships across distinct ALS therapeutic mechanisms, positioning itself as a cross-cutting patient partner rather than an advocate for any single treatment pathway.
The MNDA always joins as a participant, never as a coordinator — consistent with a patient organisation that adds value through community access and advocacy rather than scientific leadership or project management. Despite only two projects, they engaged with 21 distinct consortium partners across 8 countries, indicating participation in large, geographically dispersed clinical trial networks typical of Phase II RCTs. This scale of networking from a non-lead position suggests they are a well-connected and in-demand partner within the European ALS research community.
Connected with 21 unique consortium partners across 8 countries through just two projects, reflecting the large multi-site structure of international Phase II clinical trials. Their network spans key European neuroscience and clinical research centres, consistent with a patient organisation embedded in the broader EU ALS research ecosystem.
Unlike academic neuroscience groups or pharma partners, the MNDA offers something clinical trials genuinely cannot function without: direct, trusted access to MND patients willing to participate in research and a patient registry that supports recruitment into rare disease trials. For any consortium building an ALS clinical study, the MNDA's presence signals both patient-centred design and UK recruitment capacity — two things that reviewers and ethics boards value. Their track record across two distinct mechanistic trials (immunotherapy and neuroprotection) confirms they are not a one-programme partner.
